Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 9/20 | 0.38 |
| ▸ | CTSS | P25774 | 8/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25268638 | 0.85 | KLK5 (0.44) | CTSKCTSSITGB3ITGA2BHDAC8 | |
| SCHEMBL30802009 | 0.85 | KLK5 (0.44) | CTSKCTSSITGB3ITGA2BHDAC8 | |
| SCHEMBL30801969 | 0.81 | ITGB3 (0.51) | CTSKCTSSITGB3ITGA2BHDAC8 | |
| SCHEMBL25277595 | 0.81 | ITGB3 (0.51) | CTSKCTSSITGB3ITGA2BHDAC8 | |
| SCHEMBL18681306 | 0.79 | CA1 (0.40) | CTSKCTSSITGB3ITGA2BCTSL | |
| SCHEMBL16487110 | 0.74 | ATM (0.41) | CTSKCTSSITGB3ITGA2BHDAC8 | |
| SCHEMBL16460386 | 0.70 | CTSS (0.64) | CTSKCTSSCTSLCTSBEPHX2 | |
| SCHEMBL16460387 | 0.70 | CTSS (0.64) | CTSKCTSSCTSLCTSBEPHX2 | |
| SCHEMBL22892486 | 0.69 | FAAH (0.33) | FAAH | |
| SCHEMBL16459751 | 0.68 | CTSS (0.44) | CTSKCTSSITGB3ITGA2BCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062422-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO INC (US) | 2026-03-05 | — | — | US | disclosed |
| WO-2024054603-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062422-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | BRD4, AR, BRD3 | CTSK 3888/4885CTSS 3320/4885ITGB3 1373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.